PARKER INSTITUTE FOR CANCER IMMUNO… - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2015

Legal Domicile

Principal Officer

SEAN PARKER

Phone

4159304386

Tax Period

2024-01-01 to 2024-12-31

PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY, founded in 2015, is a mid-sized nonprofit in the Health Care sector that reported $66.9M in total revenue in fiscal year 2024. Revenue surged 183% from the prior year, signaling strong growth momentum. The organization ran a surplus of $12.5M, a strong 19% operating margin.

Mission

THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY'S (PICI) MISSION IS TO ACCELERATE THE DEVELOPMENT OF BREAKTHROUGH IMMUNE THERAPIES TO TURN ALL CANCERS INTO CURABLE DISEASES.

Program Service Accomplishments

Program 1

Expenses: $49,160,578 Revenue: $2,800,807

PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY (PICI) ENCOURAGES ADVANCES IN CANCER IMMUNOTHERAPY RESEARCH, COLLABORATION, AND DISCOVERY, AND THE TRANSLATION OF THESE ADVANCES INTO CURES AND TREATMENTS...

PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY (PICI) ENCOURAGES ADVANCES IN CANCER IMMUNOTHERAPY RESEARCH, COLLABORATION, AND DISCOVERY, AND THE TRANSLATION OF THESE ADVANCES INTO CURES AND TREATMENTS FOR THE BENEFIT OF PATIENTS. TO DO THIS, PICI PARTNERS WITH ITS CONSORTIUM OF PREEMINENT HOSPITALS AND ACADEMIC RESEARCH CENTERS TO CONDUCT ITS DISCOVERY AND CLINICAL RESEARCH AND PROVIDES ITS PARTNERS WITH SHARED RESEARCH RESOURCES, SUCH AS SCIENTIFIC EQUIPMENT, CONSUMABLES, BIOINFORMATICS ANALYSIS, AND A SPECIMEN BIOBANK. PICI ALSO FUNDS AND OTHERWISE SUPPORTS CANCER IMMUNOTHERAPY RESEARCH WITHIN ITS CONSORTIUM.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $44,804,456

Program Service Revenue $2,800,807

Investment Income $16,986,942

Other Revenue $2,354,964

TOTAL REVENUE $66,947,169

Expense Breakdown

Grants Paid $29,715,699

Salaries & Benefits $10,443,144

Fundraising Expenses $216,886

Program Expenses $49,160,578

Other Expenses $14,312,191

TOTAL EXPENSES $54,471,034

Year-over-Year Comparison

	2024	2023	Change
Revenue	$66,947,169	$23,662,636	+1.8%
Expenses	$54,471,034	$42,903,351	+0.3%
Net Income	$12,476,135	$-19,240,715	-1.6%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✓ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

$2,455,162

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
JOHN CONNOLLY PHD	CHIEF SCIENTIFIC OFFICER	40.0	Key Emp	$855,710	$71,836	$927,546
KEVIN MARKS	CHIEF LEGAL OFFICER	40.0	Key Emp	$840,863	$72,056	$912,919
UTE DUGAN MD	CHIEF MED. OFFICER THRU 6/24	20.0	Highest	$715,023	$105,296	$820,319
TARAK MODY	CHIEF BUSINESS OFFICER	40.0	Highest	$632,310	$71,836	$704,146
SHANE CORCORAN	SENIOR VP, STRAT. OPS. & COMMS	40.0	Highest	$669,429	$30,971	$700,400
SARA COBLIN	SR VP FINANCE & ADMIN.	40.0	Key Emp	$564,812	$49,885	$614,697
MARKO SPASIC	SR MEDICAL DIR, HEAD OF MED	40.0	Highest	$418,090	$9,159	$427,249
CHRISTEN DIPETRILLO	HEAD OF INTELLECTUAL PROPERTY	40.0	Highest	$354,287	$72,064	$426,351
SEAN N PARKER	CHAIR OF THE BOARD & DIRECTOR	5.0	Officer Director	$0	$0	$0
MICHAEL POLANSKY	EXECUTIVE VP & DIRECTOR	5.0	Officer Director	$0	$0	$0
TOM VAN LOBEN SELS	TREASURER & DIRECTOR	1.0	Officer Director	$0	$0	$0
JEFFREY A BLUESTONE PHD	VICE CHAIR & DIRECTOR	1.0	Director	$0	$0	$0
TONY COLES MD	DIRECTOR	1.0	Director	$0	$0	$0
ERIC ESRAILIAN MD MPH	DIRECTOR	1.0	Director	$0	$0	$0
SCOTT GOTTLIEB MD	DIRECTOR	1.0	Director	$0	$0	$0
BEN HOROWITZ	DIRECTOR	1.0	Director	$0	$0	$0
JEFF HUBER	DIRECTOR	1.0	Director	$0	$0	$0
BOB HUGIN	DIRECTOR	1.0	Director	$0	$0	$0
REED JOBS	DIRECTOR	1.0	Director	$0	$0	$0
BOB NELSEN	DIRECTOR	1.0	Director	$0	$0	$0
BRUCE PARKER PHD	DIRECTOR	1.0	Director	$0	$0	$0
BOB PITTMAN	DIRECTOR	1.0	Director	$0	$0	$0
RAMY IBRAHIM MD	DIRECTOR	1.0	Director	$0	$0	$0
MARGO GEORGIADIS	DIRECTOR	1.0	Director	$0	$0	$0
SUSAN DAWSON	SECRETARY	5.0	Officer	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	$66,947,169	$54,471,034	$223,870,654	$12,476,135
2023	$23,662,636	$42,903,351	$255,027,743	$-19,240,715
2022	$32,769,137	$62,241,652	$307,154,607	$-29,472,515
2021	$170,996,190	$52,643,221	$380,437,987	$118,352,969
2020	$66,027,113	$69,855,756	$152,630,223	$-3,828,643
2019	$162,648,564	$77,964,615	$159,252,481	$84,683,949
2018	$113,439,151	$66,202,166	$68,405,361	$47,236,985

PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY